Search
Log in
Sign up
Watch fullscreen
Eli Lilly's Mounjaro Outpaces Novo Nordisk's Ozempic In Weight Loss Effectiveness, Study Shows
Benzinga
Follow
Like
Bookmark
Share
Add to Playlist
Report
last year
Eli Lilly has come out on top in a weight loss drug competition in a recent study. The study found that patients on Lilly’s Mounjaro lost more weight than those on Novo Nordisk’s Ozempic.
Category
🗞
News
Show less
Recommended
0:38
|
Up next
Meta Apologizes for Instagram Reels Error Showing Graphic Content to Users
Benzinga
4:34
Here's why homes are so unaffordable
The Street
0:19
What Tristan Thompson wants every young athlete to know about money
The Street
0:40
Nvidia CEO Says Next-Gen AI Needs 100x More Compute Power for Advanced Reasoning. AI Models Like DeepSeek’s Will Require More Chips.
Benzinga
1:00
Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
Benzinga
1:19
Oprah Winfrey Tackles Weight Loss Drug Stigma In Prime-Time Special Amid Wegovy-Ozempic Frenzy: 'For 25 Years, Making Fun Of My Weight Was National Sport'
Benzinga
1:20
Eli Lilly Nears First Trillion Pharma Title, But Investors Caution Amid Sky-High Valuation
Benzinga
1:04
Jim Cramer Sees Eli Lilly As More Than A 'One-Trick Pony' After FDA Advisors Back Its Alzheimer's Drug: 'It's Ultimately Headed To A Trillion Dollar Valuation'
Benzinga
3:04
How End Of Month Buy And Sell Imbalances Effected Stock Movements
Benzinga
4:07
Nike Q1 Earnings Highlights: EPS Beats As North American Sales Slide, Shares Move Higher
Benzinga
4:17
Apple Stock Dips After KeyBanc Cuts Rating On iPhone Sale Concerns: What Investors Need To Know
Benzinga
1:45
Are Housing Stocks Pointing Towards A Recession? - $TOL
Benzinga
4:15
Something Is Happening In The Utilities Sector That Investors Should Watch Out For | $XLU
Benzinga
0:58
Charlie Munger Revealed What Was Left On His Bucket List Before He Died
Benzinga
1:08
As Global Markets Roil, Strategist Soothes Nerves: 'Some Normal Action Under The Surface' As 'Tech Got Way Ahead Of Itself'
Benzinga
0:39
Two Top Executives Resign as Investigation Links Deaths to Kobayashi Pharmaceutical's Rice Products
Benzinga
15:51
Dee Choubey, Co-Founder and CEO of MoneyLion - $ML
Benzinga
2:34
Disaster Stock Of The Day: Why Dick's Sporting Goods Shares Are Diving Today $DKS
Benzinga
0:31
GameStop Rockets As Roaring Kitty Returns To X: What Does His Tweet Signal Ahead Of Q3 Earnings?
Benzinga
7:13
From Meme to Market: Apu Apustaja's Journey to a $380M Market Cap
Benzinga
2:08
Does The Dip In The S&P500 Indicate A New Downtrend Or Just A Pullback?
Benzinga
4:15
Go Woke, Go Broke, ETF and GUNZ ETF, Matthew Tuttle, Tuttle Capital Management
Benzinga
0:45
Vivek Ramaswamy Breathes New Life Into Beaten Down BuzzFeed Stock: What Investors Need To Know
Benzinga
1:31
Why Is The Fed Still So Aggressive? - Jeremy Schwartz, Chief Investment Officer at WisdomTree
Benzinga
6:17
A Deep Dive Analysis Into Nvidia Stock With Wall Street Tech Veteran, Paul Meeks
Benzinga